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Osimertinib is an oral epithelial growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used primarily in the treatment of
metastatic non-small cell lung cancer. It is usually well tolerated with less than 5% of patients developing significant pulmonary
toxicity from the medication, typically within the first few months after initiation. Previously reported pulmonary adverse
reactions include pneumonitis (nonspecific interstitial pneumonia or other forms of acute interstitial process), fleeting
asymptomatic infiltrates on imaging, and eosinophilic pneumonia. We present an interesting case of a 65-year-old female with
recurrent metastatic adenocarcinoma of the lung, treated with Osimertinib for 4 months, who developed a previously
unreported toxicity of diffuse alveolar hemorrhage (DAH) requiring mechanical ventilatory support.
1. Introduction
Diffuse alveolar hemorrhage (DAH) is a potentially life-
threatening disorder characterized by respiratory failure,
hemoptysis, diffuse infiltrates on chest imaging, and blood
loss anemia.
Prompt recognition and urgent evaluation with bron-
choscopy are necessary for diagnosis. DAH is caused by a
wide range of clinical entities. Common etiologies include
capillaritis, vasculitis, and diffuse alveolar damage or from
an extensive list of medications and toxins such as amioda-
rone, nitrofurantoin, cocaine, and tumor necrosis factor-
(TNF-) alpha inhibitors [1]. To date, there have been no
previously reported cases of Osimertinib causing DAH in
the literature.
Osimertinib is an oral epithelial growth factor receptor
tyrosine kinase inhibitor (EGFR-TKI) used primarily in the
treatment of metastatic non-small cell lung cancer (NSCLC).
It is routinely used in patients with metastatic T790M-
positive NSCLC who have disease progression during or after
EGFR-TKI therapy [2]. Osimertinib can now be prescribed
as a first-line agent regardless of the presence of T790M. Dur-
ing early clinical trials [3], the most common pulmonary
complication was interstitial lung disease, which occurred
in about 4% of patients. In general, the drug is felt to have a
favorable side effect profile and tolerability.
We present an interesting case of a previously unreported
toxicity with the use of Osimertinib.
2. Case Presentation
The patient is a 65-year-old female who was previously diag-
nosed with moderately differentiated, invasive adenocarci-
noma after a right upper lobectomy in 2013. The tumor
was positive for EGFR mutation, KRAS wild type, ALK neg-
ative, CK7 positive, CK20 negative, and TTF negative. At that
time, no chemotherapy or radiation was required. In 2014,
the patient had a recurrence of her disease with a metastasis
to mediastinal subcarinal lymph node. Over the next four
years due to disease progression or inability to tolerate agents
(e.g., development of acute pancreatitis from erlotinib), the
patient was treated with multiple antineoplastic agents
including bevacizumab, pemetrexed, durvalumab, tremeli-
mumab, erlotinib, and afatinib. These were all discontinued
over 6 months prior to this admission to the hospital. She
also received palliative radiation to the right mediastinal
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mass as well as to several metastatic spine lesions in the cer-
vical and thoracic spine during 2017. Follow-up staging
imaging did not show any evidence of radiation pneumonitis
or fibrosis. In early 2018, she underwent biopsy of metastatic
liver lesions, found to be adenocarcinoma of the lung pri-
mary with EGFR exon 19 deletion and T790M mutations.
In April 2018, she was started on Osimertinib 80mg daily,
which she tolerated well for approximately four months.
A staging CT was completed in June of 2018, which showed
response to therapy as evidenced by a decrease in size of
the right infrahilar mass, adenopathy, pulmonary nodules,
and hepatic metastases. In addition, her previously noted
brain metastasis was no longer seen on her brain MRI. In
August 2018, she required an admission to an outside facil-
ity due to symptoms suggestive of congestive heart failure.
She was diuresed and diagnosed with nonischemic cardio-
myopathy. Her heart failure remained well compensated
on goal-directed medical therapy and diuretics. Other past
medical history is notable for hypertension, acid reflux,
emphysema, and iron deficiency anemia. She is not pre-
scribed any antiplatelet or anticoagulation agents. She has
several allergies to antibiotics and was previously intolerant
to subcutaneous heparin.
The patient was admitted to our facility in September
2018 due to progressive dyspnea, fatigue, and weakness of
several weeks of duration. She was initially managed as
hospital-acquired pneumonia in an immunocompromised
host with broad-spectrum antimicrobials, aggressive bron-
chodilators, and intravenous corticosteroids. Within 24
hours of admission, transfer to the intensive care unit was
facilitated due to worsening respiratory distress requiring
noninvasive positive pressure ventilation which eventually
progressed to require mechanical ventilation. At this time,
her exam was remarkable for predominant left-sided rhonchi
and rales. Laboratory analysis was unremarkable except a
severe acute respiratory acidosis of pH7.18 and PCO2 of
54mmHg. Upon arrival, her WBC count was 7 6 × 103/μL,
hemoglobin was 8.5 g/dL, and platelets were 305 × 103/μL,
and she had normal coagulation panel and B-type natri-
uretic peptide (BNP). A CT chest with contrast demonstrated
a consolidation in the left lung suspicious for pneumonia and
small effusions bilaterally with associated atelectasis (Figure 1).
Her antibiotics were continued.
Due to the progressive respiratory failure, a bronchos-
copy was performed. The bronchoscopy revealed inflamed
airways (left>right) and increasingly hemorrhagic return
on sequential lavages (Figure 2) from the lingular segment
of the left upper lobe. Bronchoalveolar lavage (BAL) RBC
counts were increasing significantly in sequential samples
(42,000/μL, 190,000/μL, and 230,000/μL). She was diagnosed
with DAH with predominant left-sided parenchymal involve-
ment. She was initiated with pulse dose methylprednisone
250mg IV every 6 hours for 3 days. Her ventilator settings
improved significantly after the initiation of pulse dose sys-
temic steroids. After three days of IV steroids, we decided
to repeat the bronchoscopy due to continued small amount
of blood-tinged tracheal aspirates requiring in-line suction.
On repeat bronchoscopy, the airway inflammation had
diminished considerably. There was no visible bleeding. We
elected to repeat a sequential lavage in the lingular segment,
which was dramatically less hemorrhagic (Figure 3). The
Figure 1: Representative axial CT for PE image of our patient upon
admission to the intensive care unit showing dense airspace
opacities involving predominantly the left upper lobe and small
pleural effusion.
Figure 2: Initial sequential lavages from the patient’s lingular
segment demonstrating obvious DAH.
Figure 3: Repeat sequential lavage after 3 days of methylprednisone
from lingular segment demonstrating an improvement in her DAH.
Figure 4: Axial CT chest with contrast approximately 3 months
later in an outpatient follow-up, demonstrating a marked
improvement of her infiltrate.
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RBC counts from the sequential lavage were 5,250/μL,
6,750/μL, and 11,500/μL. Microbiology from BAL was unre-
markable. The patient was transitioned to oral prednisone
1mg/kg daily. She was successfully weaned from mechanical
ventilation and eventually discharged from the hospital with-
out a need of any supplemental oxygen.
A comprehensive standard etiological assessment for
DAH was unremarkable including ANCA vasculitis panel
and anti-GBM antibodies. Despite her diagnosis of nonis-
chemic cardiomyopathy, the patient was not clinically in
decompensated heart failure at any point in her admission.
Upon medication review, Osimertinib 80mg daily was the
only new medication the patient had initiated in the prior
four months. Osimertinib was discontinued in consultation
with medical oncology and was held at her discharge from
the hospital. She was discharged on a prolonged prednisone
taper. A follow-up CT of the chest demonstrated resolution
of the opacities in the left upper lobe (Figure 4).
3. Discussion
In recent years, several molecularly defined subsets of non-
small cell lung cancer (NSCLC) with specific somatic “driver”
mutations, thought to be responsible for the initiation and
maintenance of tumor growth, have been identified. Among
these mutations, EGFR alterations are the most common,
present in about 10% to 15% of patients with NSCLC in
the United States. EGFR belongs to the ERBb superfamily
of tyrosine kinase receptors, which mediate tumor prolifera-
tion, invasion, metastasis, resistance to apoptosis, and angio-
genesis. EGFR-TKI (first generation: erlotinib and gefitinib;
second generation: afatinib; and most recent: Osimertinib)
significantly prolong progression-free survival in patients
with advanced NSCLC that contains an activating mutation
in EGFR compared with platinum-based chemotherapy
doublets [2].
Osimertinib is usually well tolerated with less than 5%
of patients developing toxicity from the medication, usu-
ally within the first few months. Previously reported pul-
monary adverse reactions include pneumonitis including
nonspecific interstitial pneumonia [3–6] or other acute
interstitial processes [3, 6], fleeting asymptomatic infil-
trates on imaging [7, 8], and eosinophilic pneumonia [9].
Previously reported pulmonary toxicities are summarized
in Table 1. All of the patients had improvement in their
pulmonary complaints after discontinuation of the medica-
tion. There seemed to be no typical time frame or age/sex
predilection in the previous case reports. Pneumonitis
Table 1: Summary of previously reported cases of pulmonary toxicities of Osimertinib.
Article Patient age/sex
Onset of
symptoms
Symptoms Diagnosis Treatment Outcome
Mamesaya et al. [4] 38 F 31 days
Dyspnea and
low-grade fever
Drug-induced
interstitial lung
disease (ILD)
Withdrawal of
medication
Resolution of
ILD
but progression
of malignancy
Matsumoto et al. [5] 75 M 20 days
Generalized
weakness
and dyspnea
Drug-induced
ILD (NSIP)
Methylprednisone
500mg daily for
3 days, then
prednisone
40mg daily
Resolution of
ILD following
steroid taper
Yang et al. [3]
8 patients
(no specifics)
Average of
5.1 months
ILD and one case
of pneumonitis
Not described
3 patients
resolved,
2 remained at end
of study, and
3 patients
deceased
Nie et al. [6] 32 M 4.5 months
Cough and
dyspnea
Acute ILD
Dose reduction
to 80mg every
other day and
dexamethasone
10mg daily
Improvement in
infiltrates and
symptoms
Lee et al. [7] 15 patients 24 weeks None
Asymptomatic
pulmonary
opacities
None
No adverse
events
reported
Noonan et al. [8]
4 males
(average age 57)
and 3 females
(average age 43)
8 weeks
mean onset
None
Asymptomatic
pulmonary opacities,
mostly nodules and
ground glass opacities
None
All patients had
good outcomes
Tachi et al. [9] 77 F 14 days
Fever and
hypoxia
Eosinophilic
pneumonia due
to Osimertinib
Withdrawal of
medication
Gradual
improvement
in her symptoms
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generally appeared sooner than the ILD, within the first
month of therapy [4, 5]. ILD, including acute ILD, was a
later complication at about 4 months of therapy in the
previous case reports [3, 6]. The asymptomatic pulmonary
opacities occurred at approximately 8-24 weeks of therapy
[7, 8], whereas the eosinophilic pneumonia occurred at
2 weeks of therapy [9]. Some patients were also given steroids
which seemed to be an effective adjunct to medication dis-
continuation in the improvement in respiratory symptoms.
In addition to respiratory adverse reactions, a very small
number of patients seem to have developed cardiac adverse
drug reactions to Osimertinib (Table 2). Watanabe et al.
and Oyakawa et al. described two females, aged 78 and 84,
respectively, who developed symptoms of congestive heart
failure and dilated cardiomyopathy with no other obvious
cause during their course of treatment with Osimertinib
[10, 11]. One was 21 days and the other was 34 weeks
into treatment [10, 11]. These patients also improved with
drug discontinuation and goal-directed medical therapy as
well as diuretics. One patient described by Schiefer et al.,
who was a 61-year-old female, developed a significant QT
prolongation after 11 months of treatment with Osimerti-
nib, which quickly normalized after discontinuation of the
medication [12].
To our knowledge, this is the first known case reporting
diffuse alveolar hemorrhage associated with Osimertinib. Cli-
nicians should be cognizant of this new potential adverse
reaction in addition to the already recognized pulmonary
and cardiac toxicities of the medication. Urgent evaluation
with bronchoscopy and serial bronchoalveolar lavage is
critical for quick recognition and diagnosis. Our patient
responded very well to discontinuation of the medication
and pulse dose steroids with subsequent slow taper. The
optimal treatment algorithm is not known but high-dose
corticosteroids are likely very effective in bringing prompt
resolution to the syndrome. Further investigations into the
management of this subset of patients could be undertaken.
With advent of genetic analysis and targeted therapy
for lung cancers, there is an increased use of therapy which
targets specific genetic mutations. Considering more preva-
lent use of EGFR-TKI, particularly Osimertinib as front-
line therapy for NSCLC, it is highly significant to recognize
uncommon adverse reactions. Our case represents the
unique side effect of diffuse alveolar hemorrhage leading to
severe respiratory failure needing mechanical ventilation
with the use of Osimertinib. This paper provides the review
of previously reported pulmonary adverse reactions from
Osimertinib and highlights the ongoing need for prompt
recognition and appropriate management measures to be
undertaken during the course of therapy.
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